Predict your next investment

BioVentrix company logo
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
bioventrix.com

See what CB Insights has to offer

Stage

Convertible Note - IV | Alive

Total Raised

$200.77M

Last Raised

$40.76M | 9 mos ago

About BioVentrix

BioVentrix (CHF Technologies) is focused on developing advanced clinical solutions that treat heart failure patients. The company's Blue Egg Sizer is used in conjunction with Left Ventricular Reconstruction (LVR). BioVentrix's Heart Failure Program helps hospitals create the kind of financial model, operations plan, and data management necessary to run an integrated care program.

BioVentrix Headquarter Location

12647 Alcosta Boulevard Suite 400

San Ramon, California, 94583,

United States

925-830-1000

Latest BioVentrix News

BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors Rinda K. Sama and Andrew G. Hinson to Its Board of Directors

Jul 21, 2021

July 21, 2021 07:30 AM Eastern Daylight Time SAN RAMON, Calif.--( BUSINESS WIRE )-- BioVentrix, Inc. , a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years’ experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (Nasdaq: AXNX). In addition, two other accredited public company directors and experienced life science executives have been added to the Company’s board of directors. Andrew G. Hinson currently serves as a member of the board of directors at BioLife Solutions, Inc. (Nasdaq: BLFS). Mr. Hinson has over 30 years’ experience in pharmaceutical, biotechnology and medical device development that includes specific expertise in congestive heart failure, clinical research and development, regulatory affairs, and business development. Hinson holds a B.S. in Biological Sciences from the University of Cincinnati. Rinda K. Sama currently serves as the chief operating officer of Axonics, Inc. Mr. Sama has over 20 years’ experience in medical devices and is an expert in manufacturing and operations, as well as worldwide regulatory affairs. Sama holds a M.S. in Biomedical Engineering from the University of Southern California and an MBA from the University of California, Irvine. “This is an important time in the Company’s history. BioVentrix has an accomplished and experienced CEO in Jim Dillon who now has a number of industry experts to provide support and guidance as the Company seeks to complete its PMA study, gain FDA approval and execute a successful IPO,” said Raymond W. Cohen, chairman of BioVentrix. The additions of Mr. Sama and Mr. Hinson brings the total of independent medical device industry experts on the BioVentrix board to six, including CEO Jim Dillon and current board members, Steve Healy and George Fazio. Jim Dillon, CEO of BioVentrix, commented, “The Revivent TC™ system, which has achieved Breakthrough Designation by the U.S. FDA, is designed to treat congestive heart failure (CHF) patients with an enlarged left ventricle for which, until now, there has been no treatment. Clinical results continue to be impressive and reimbursement is already in place. We believe the combination of these factors will allow for a highly successful commercialization and rapid adoption in the United States.” About Cardiomyopathy Cardiomyopathy represents a collection of diverse conditions of the heart muscle. These diseases have many causes, and symptoms that affect people of all ages and races. When cardiomyopathy occurs, the normal muscle in the heart can thicken, stiffen, thin out, or fill with substances the body produces that do not belong in the heart. As a result, the heart muscle’s ability to pump blood is reduced, which can lead to an irregular heart rhythm, the backup of blood into the lungs or rest of the body, and death. Cardiomyopathy can be acquired—developed because of another disease, condition, or factor—or inherited. The cause is not always known. About BioVentrix BioVentrix , Inc., is a privately held medical device company headquartered in San Ramon, California. The Company’s mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy. BioVentrix’s Revivent TC™ system received the CE Mark and is currently pending FDA approval in the United States. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioVentrix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioVentrix is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,589 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. Excludes CDMOs/CMOs. *Columns updated as regularly as possible.

BioVentrix Patents

BioVentrix has filed 56 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiology
  • Heart diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/2/2015

7/6/2021

Cardiac anatomy, Congenital heart defects, Cardiology, Cardiac arrhythmia, Cardiovascular physiology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/2/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/6/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cardiac anatomy, Congenital heart defects, Cardiology, Cardiac arrhythmia, Cardiovascular physiology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

BioVentrix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioVentrix Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.